C h a p t e r 2 0
Heart Failure and Circulatory Shock
511
16. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy
and failure.
N Engl J Med.
1999;341(17):1276–1283.
17. Chatterjee K. Pathophysiology of systolic and diastolic failure.
Med Clin North Am.
2012;96:891–899.
18. Brouwers FB, Hillege HL, van Gist WH, et al. Comparing new
onset heart failure with reduced ejection fraction and new onset
heart failure with preserved heart failure.
Curr Heart Fail Rep.
2012;9:363–368.
19. Redfield M. Heart failure with normal ejection fraction. In:
Bonow R, Mann DL, Zipes DP, et al., eds.
Braunwald’s Heart
Disease: A Textbook of Cardiovascular Medicine
. 9th ed.
Philadelphia, PA: Elsevier Saunders; 2012:586–600.
20. Bortaug BA, Paulus WJ. Heart failure with preserved ejection
fraction: pathophysiology, diagnosis, and treatment.
Eur Heart J.
2011;32:670–679.
21. Fletcher L, Thomas D. Congestive heart failure: understanding
the pathophysiology and management.
J Am Acad Nurse Pract.
2001;13,249–257.
22. McMurray JJV. Systolic heart failure.
N Engl J Med.
2010;362(3):228–238.
23. Wu EB, Yu CM. Management of diastolic heart failure: a
practical review of pathophysiology and treatment trial data.
Int J Clin Pract.
2005;59:1239–1246.
24. Aurigemma GP, Gaasch WH. Diastolic heart failure.
N Engl J
Med.
2004;351:1095–1105.
25. Haney S, Sur D, Xu Z. Diastolic heart failure: a review and primary
care perspective.
J Am Board Fam Pract.
2005;18:189–195.
26. Guglin M, Verma S. Right side of heart failure.
Heart Fail Rev.
2012;17:511–527.
27. Budev MM, Arroliga AC, Wiedemann HP, et al. Cor pulmonale:
an overview.
Semin Respir Crit Care Med.
2003;23:233–243.
28. Greenberg B, Kahn AM. Clinical assessment of heart failure.
In: Bonow R, Mann DL, Zipes DP, et al., eds.
Braunwald’s
Heart Disease: A Textbook of Cardiovascular Medicine
. 9th ed.
Philadelphia, PA: Elsevier Saunders; 2012:505–516.
29. Calvin AD, Albuquerque FN, Adachi T, et al. Obstructive sleep
apnea and heart failure.
Curr Treat Options Cardiovasc Med.
2009;11(6):447–454.
30. Brack T. Cheyne-Stokes respiration in patients with congestive
heart failure.
Swiss Med Wkly.
2003;133:605–610.
31. Pureza V, Florea VG. Mechanisms for cachexia in heart failure.
Curr Heart Fail Rep.
2013;10(4):307–314.
32. Crijns HJ, Tjeerdsma G, DeKam PJ, et al. Prognostic value of the
presence and development of atrial fibrillation in patients with
advanced chronic HF.
Eur Heart J.
2000;21:1238–1245.
33. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure
syndrome: current state and framework for future research.
Circulation.
2005;112:3958–3968.
34. Mebazaa A, Gheorghliade M, Piña IL. Practical
recommendations for prehospital and early in-hospital
management of patients presenting with acute heart failure
syndromes.
Crit Care Med.
2008;36(1 suppl):S129–S139.
35. Chen HH, Schrier RW. Pathophysiology of volume
overload in acute heart failure syndromes.
Am J Med.
2006;119(12A):S11–S26.
36. Kale P, Fang JC. Devices in acute heart failure.
Crit Care Med.
2008;36(1 suppl):S121–S128.
37. Clerico A, Vittorini S, Passino C. Circulating forms of the B-type
natriuretic peptide prohormone: pathophysiologic and clinical
considerations.
Adv Clin Chem.
2012;58:31–44.
38. Bridges EJ. Hemodynamic monitoring. In: Woods SL,
Froelicher ESS, Motzer SU, et al., eds.
Cardiac Nursing
.
5th ed. Philadelphia, PA: Lippincott Williams & Wilkins;
2005:478–526.
39. Riegel B, Moser DK, Anker SD, et al. State of the science:
promoting self-care in persons with heart failure: a scientific
statement from the American Heart Association. American Heart
Association Council on Cardiovascular Nursing; American Heart
Association Council on Cardiovascular Nursing; American
Heart Association Council on Clinical Cardiology; American
Heart Association Council on Nutrition, Physical Activity, and
Metabolism; American Heart Association Interdisciplinary
Council on Quality of Care and Outcomes Research.
Circulation.
2009;120(12):1141–1163.
40. Katzung BG. Drugs used in heart failure. In: Katzung BG,
Masters SB, Trevor AJ, eds.
Basic & Clinical Pharmacology
.
12th ed. New York, NY: McGraw-Hill; 2012.
41. Slaughter MS, Pagani FD, Rogers JG. Clinical management of
continuous-flow left ventricular assist devices in advanced heart
failure.
J Heart Lung Transplant.
2010;29:S1–S39.
42. Wheeldon DR. Mechanical circulatory support: state of the art
and future perspectives.
Perfusion.
2003;8:233–243.
43. Patel ND, Barreiro CJ, Williams JA, et al. Surgical ventricular
remodeling for patients with clinically advanced congestive HF
and severe left ventricular dysfunction.
J Heart Lung Transplant.
2005;24:2202–2210.
44. Thomas S, Rich MW. Epidemiology, pathophysiology, and
prognosis of heart failure in the elderly.
Clin Geriatr Med.
2007;23:1–10.
45. Rich MW. Heart failure in older adults.
Med Clin North Am.
2006;90:863–885.
46. Schwartz JB, Zipes DP. Cardiovascular disease in the
elderly. In: Bonow RO, Mann DL, Zipes DP, et al., eds.
Braunwald’s Heart Disease: A Textbook of Cardiovascular
Medicine
. 9th ed. Philadelphia, PA: Elsevier Saunders;
2012:1727–1756.
47. Abdelhafiz AH. Heart failure in older people: causes, diagnosis,
and treatment.
Age Ageing.
2002;31:29–36.
48. Holmes CL, Walley KR. The evaluation and management of
shock.
Clin Chest Med.
2003;24:775–789.
49. Graham CA, Parke TRJ. Critical care in the emergency
department: shock and circulatory support.
Emerg Med J.
2005;22:17–21.
50. Guly HR, Bouamra O, Spiers M, et al. Vital signs and estimated
blood loss in patients with major trauma: testing the validity of
the ATLS classification of hypovolaemic shock.
Resuscitation.
2011;82:556–559.
51. Dutton RP. Current concepts in hemorrhagic shock.
Anesthesiol
Clin.
2007;25:23–34.
52. Reinhart K, Perner A, Sprung CL, et al. Consensus statement of
the ESICM task force on colloid volume therapy in critically ill
patients.
Intensive Care Med.
2012;3:368–383.
53. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid
resuscitation in critically ill patients.
Cochrane Database Syst
Rev.
2013;2:CD000567.
54. Hollenberg SM. Vasoactive drugs in circulatory shock.
Am J
Respir Crit Care Med.
2011;183:847–855.
55. Buerke M, Lemm H, Dietz K. Pathophysiology, diagnosis,
and treatment of infarction-related cardiogenic shock.
Herz.
2011;36:73–83.
56. Antman EM, Morrow DA. ST-elevation myocardial infarction:
management. In: Bonow RO, Mann DL, Zipes DP, et al., eds.
Braunwald’s Heart Disease: A Textbook of Cardiovascular
Medicine
. 9th ed. Philadelphia, PA: Elsevier Saunders;
2012:1111–1170.
57. Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends
(1975 to 2005) in the magnitude of, management of, and
hospital death rates associated with cardiogenic shock in patients
with acute myocardial infarction: a population-based perspective.
Circulation.
2009;119:1211–1219.
58. Abdel-Qadir HM, Ivanov J, Austin PC, et al. Temporal trends
in cardiogenic shock treatment and outcomes among Ontario
patients with myocardial infarction between 1992 and 2008.
Circ Cardiovasc Qual Outcomes.
2011;4:440–447.
